Microglial transplantation increases amyloid-β clearance in Alzheimer model rats  by Takata, Kazuyuki et al.
FEBS Letters 581 (2007) 475–478Microglial transplantation increases amyloid-b clearance in
Alzheimer model rats
Kazuyuki Takataa, Yoshihisa Kitamuraa,*,1, Daijiro Yanagisawaa, Shigehiro Morikawab,
Masahito Moritab,e, Toshiro Inubushib, Daiju Tsuchiyaa, Saori Chishiroa, Mana Saekia,
Takashi Taniguchia, Shun Shimohamac, Ikuo Tooyamad,*,1
a Department of Neurobiology and 21st Century COE Program, Kyoto Pharmaceutical University, Misasagi, Yamashina-ku, Kyoto 607-8414, Japan
b Biomedical MR Science Center, Shiga University of Medical Science, Seta Tsukinowa-cho, Otsu 520-2192, Japan
c Department of Neurology, Sapporo Medical University, School of Medicine, S1W17, Chuo-ku, Sapporo 060-8556, Japan
d Molecular Neuroscience Research Center, Shiga University of Medical Science, Seta Tsukinowa-cho, Otsu 520-2192, Japan
e PRESTO, Japan Science and Technology Agency, 4-1-8 Honcho Kawaguchi, Saitama 332-0012, Japan
Received 1 December 2006; revised 29 December 2006; accepted 8 January 2007
Available online 16 January 2007
Edited by Jesus AvilaAbstract Immunization with amyloid-b (Ab) peptides, a thera-
peutic approach in Alzheimer’s disease (AD), reduces brain Ab,
and microglial Ab phagocytosis has been proposed as an Ab-low-
ering mechanism. We transplanted rat microglia into the rat lat-
eral ventricle just after intra-hippocampal Ab injection, and then
investigated the contribution of exogenous microglia to Ab clear-
ance. Migration of exogenous microglia from the lateral ventricle
to Ab plaque was detected by magnetic resonance imaging and
histochemical analysis, and the clearance of Ab was increased
by transplantation. These results suggest the possible usefulness
of exogenous microglia to the therapeutic approach in AD.
 2007 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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Accumulation of amyloid-b (Ab) is a pathological hallmark
of Alzheimer’s disease (AD) and is thought to be a primary
event in AD pathologies in the amyloid hypothesis [1]. On the
other hand, accumulated Ab in AD brains is surrounded by
activated microglia [2]. Among recent studies that support the
amyloid hypothesis, immunization with Ab peptides using
transgenic mouse models of AD indicated the eﬀective reduc-
tion of brain Ab and restoration of cognitive functions [3–6].Abbreviations: Ab, amyloid-b; AD, Alzheimer’s disease; DAB, 3,30-
diaminobenzidine; ELISA, enzyme-linked immunosorbent assay;
GFAP, glial ﬁbrillary acidic protein; HVJ-E, hemagglutinating virus
of Japan envelop; Iba1, ionized calcium binding adaptor molecule 1;
MAP2, microtubule-associated protein-2; MRI, magnetic resonance
imaging; PBS, phosphate-buﬀered saline; TBS, tris-buﬀered saline;
TNF, tumor necrosis factor
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ing mechanism of Ab immunization, and Ab phagocytosis of
exogenously administered microglia was indicated in experi-
mental ex vivo study using unﬁxed brain sections from both
AD cases and transgenic mice [4]. These ﬁndings suggest the po-
tential of exogenous microglia for the cell therapeutic approach
in AD; however, experimental evidence is insuﬃcient to con-
sider whether the phagocytic function of exogenous microglia
eﬀectively contributes to Ab clearance in in vivo brains.
2. Materials and methods
2.1. Alzheimer model rat and microglial transplantation
Animal experiments were carried out in accordance with the guide-
lines of the National Institutes of Health, and protocols were approved
by the Committee for Animal Research at Kyoto Pharmaceutical Uni-
versity. For stereotaxic microinjection, male Wistar rats were immobi-
lized in a Kopf stereotaxic frame. Coordinates were set according to a
rat brain atlas [7]. Rats were microinjected with saline and 1 lg of syn-
thetic human Ab1-42 (Ab42) peptide (AnaSpec) into the right and left
hippocampus, respectively (i.e., 3.8 mm caudal from the bregma,
2.0 mm right and left lateral, 4.0 mm ventral, Fig. 1B). Lyophilized
human Ab42 was dissolved at a high concentration and aliquots were
kept at 80 C. Subsequently, Ab42 was diluted with phosphate-
buﬀered saline (PBS), and then immediately injected into the rat hippo-
campus. Microglial pure culture was prepared as described previously
[8]. For magnetic resonance imaging (MRI), microglia (over 97% pure)
were labeled with super-paramagnetic iron particles (Resovist; Nihon
Schering K.K.) using the hemagglutinating virus of Japan envelop
(HVJ-E; GenomONE, Ishihara Sangyo Kaisha Ltd.) vector as
described previously [9]. Resovist-labeled microglia (Fig. 1A, inset)
were re-suspended in PBS to a ﬁnal concentration of approximately
1.0 · 106 cells in 5 ll, and then transplanted to the left lateral ventricle
(i.e., 0.2 mm caudal from the bregma, 1.2 mm left lateral, 3.8 mm ven-
tral, Fig. 1A) just after Ab injection.
2.2. MRI
At one and eight days after Ab42 and microglial injection, magnetic
resonance (MR) images were acquired with a 7T Unity Inova MR
scanner (Varian). Gradient echo images of the rat brain were acquired
in sequential 8 slices of 1-mm thickness of the coronal plane with 300-
ms repetition time, 15-ms echo time, 30 ﬂip angle, 35 · 35-mm2 ﬁeld
of view, 256 · 128 matrices, and one excitation for each phase encod-
ing step. During MRI sessions, the spontaneously breathing animals
were anesthetized with 1.5% isoﬂurane in 50% O2 and 50% air.
2.3. Histochemistry
At nine days after Ab42 and microglial injection, rats were perfused
with cold ﬁxative consisting of 4% paraformaldehyde in 100 mM phos-
phate buﬀer. Brain sections were cut into 20 lm thick slices with ablished by Elsevier B.V. All rights reserved.
Fig. 1. Resovist-labeled rat microglia were transplanted (inset in A)
into the left lateral ventricle (green in A) just after intra-hippocampal
injections of saline (blue in B) and Ab42 peptide (red in B). MR images
in the control rat (non-microglial transplantation) at 1 day after Ab
injection are shown in (C) and (D). In MR images of rat grafted with
microglia, the accumulation of exogenous microglia was detected as
dark signals in the lateral ventricle (green arrowheads) and Ab-injected
site (orange arrowheads) at 1 day (E and F) and 8 days (G and H) after
transplantation. Bars = 50 lm (inset in A), 2 mm (C–H).
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bodies, including anti-Ab (clone 6E10, Chemicon), anti-ionized cal-
cium binding adaptor molecule 1 (Iba1; Wako), and anti-CD68
(clone ED1, Serotec) antibodies. Other series were incubated with
anti-microtubule-associated protein-2 (MAP2; Sigma), anti-glial ﬁbril-
lary acidic protein (GFAP; Chemicon), and anti-oligodendrocytes
(Chemicon) antibodies. Sections were followed by biotinylated second-
ary antibody, and then incubated with a Vectastain ABC elite kit (Vec-
tor). Subsequently, labeling was revealed with 3,3 0-diaminobenzidine
(DAB) with or without nickel ammonium. Counterstaining for ferric
iron (Resovist) was examined by the Prussian blue method. In brief,
sections were incubated for 30 min with 1% potassium ferrocyanide
in 1% HCl at room temperature to stain iron particles blue.
2.4. ELISA
The amounts of Ab42 and tumor necrosis factor (TNF)-a in hippo-
campi were measured by enzyme-linked immunosorbent assay (ELI-
SA) kits for human Ab42 and rat TNF-a (BioSource) according to
the manufacturer’s instructions, respectively. In brief, hippocampi on
the Ab-injected side were dissected and then the cytosolic fraction
was extracted by 500 ll of tris-buﬀered saline (TBS) and the formic
acid (FA) fraction extracted from the pellet by 500 ll of FA was pre-pared as described previously [10]. In our previous study, almost all
Ab42 was recovered from the FA fraction but little or none was found
in the TBS fraction in Ab-injected rats [11,12]; therefore, the amount of
Ab42 in the FA fractions was measured. Alternatively, expression lev-
els of TNF-a were determined in TBS fractions as a marker for
microglial activities. Results are given as the means ± standard error
of the mean (S.E.M.). The statistical signiﬁcance of diﬀerences was
determined by analysis of variance (ANOVA), and the Bonferroni/
Dunn test was carried out for post hoc comparisons.3. Results
3.1. Exogenously transplanted microglia were detected on Ab
deposit by MRI
Transplanted microglia labeled with Resovist were traced by
T2-weighted MRI at a magnetic ﬁeld of 7 T (Fig. 1C–H). In the
control rat, which was an Ab42-injected rat without microglial
transplantation, there were no obvious changes in MR signals
in both sides of lateral ventricles (Fig. 1C) and hippocampi
(Fig. 1D). In the Ab42-injected rat transplanted with Reso-
vist-labeled microglia, a dark area indicating the decrease of
MR signals was detected along with the left lateral ventricle
at 1 day after transplantation (Fig. 1E). Furthermore, the dark
area appeared in the Ab42-injected left hippocampus (Fig. 1F).
At eight days following transplantation, the dark area in the
left lateral ventricle was decreased (Fig. 1G), while that in
the left hippocampus was still clearly detected (Fig. 1H). These
results suggest that iron particles phagocytosed by microglia
reduce the MR signals and the dark areas may indicate the
accumulation of exogenous microglia.
3.2. Accumulation of exogenous microglia on Ab deposit was
conﬁrmed by histochemical analysis
The day after the MRI operation, the rat was sacriﬁced and
then hippocampal sections were prepared.At theAb42 injection
site (Fig. 2A), brown-colored microglia expressing Iba1
(Fig. 2B) or CD68 (phagocytic marker; Fig. 2C) inﬁltrated
and some contained blue iron particles visualized by the Prus-
sian blue method (Fig. 2D and E). We have reported recently
that MAP2 immunoreactivity (neuronal marker) was moder-
ately decreased by the neurotoxicity of Ab42 in the Ab42-in-
jected rat [12]. In this study, we also found moderate loss of
MAP2 immunoreactivity at the Ab42 injection site (Fig. 2F).
In addition, oligodendrocytes (Fig. 2G) surrounded the Ab42
injection site and GFAP-immunoreactive astrocytes (Fig. 2H)
were slightly activated in the region adjacent to the Ab deposit.
Blue iron was not co-localized with the immunoreactivity of
MAP2 (Fig. 2I), oligodendrocytes (Fig. 2J), or GFAP
(Fig. 2K); thus, iron-containing cells expressed a microglial
marker. These results suggest that exogenously transplanted
microglia in the lateral ventricle may migrate to the hippocam-
pus and accumulate on the Ab deposit together with endoge-
nous microglia.
3.3. Microglial transplantation increased Ab clearance
and the expression level of TNF-a in rat hippocampus
Subsequently, we measured the amount of human Ab42 in-
jected into the rat hippocampus (Fig. 3A). Although the
amount of Ab42 was gradually reduced even in control rats,
reduction was signiﬁcantly increased by microglial transplan-
tation at 7 and 14 days after the injection of Ab42. Further-
more, we measured the expression levels of TNF-a, a
Fig. 3. Amounts of Ab42 (A) and TNF-a (B) in rat hippocampus with
(hatched column) or without (black column) microglial transplanta-
tion were measured by ELISA. ***P < 0.001 vs. the value in control
rats at day 0. P < 0.05 vs. value at the same time point. n: number of
Fig. 2. The day after the MRI operation, rats were sacriﬁced and then
ﬁxed brain sections were prepared. One series of serial hippocampal
sections in the Ab-injected site was stained with antibodies against Ab
(A), Iba1 (marker for microglia; brown in B and D), and CD68
(phagocytic marker; brown in C and E). Another series was stained
with antibodies against MAP2 (marker for neurons; brown in F and I),
oligodendrocytes (ODCs; brown in G and J), and GFAP (marker for
astrocytes; brown in H and K). Resovist was visualized by the Prussian
blue method (blue particles in B–K). High magniﬁcations of squares in
B, C, F, G, and H are shown in D, E, I, J, and K, respectively. Scale
bars = 100 lm (A–C and F–H), 20 lm (D, E and I–J). Asterisks and
daggers indicate identical blood vessels in A–C and F–H, respectively.
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activities (Fig. 3B). The amounts of TNF-a were slightly in-
creased in control rats. At 7 and 14 days after the injection
of Ab42, the amount of TNF-a in rats transplanted with
microglia was signiﬁcantly higher than those in control rats.
These results indicate that exogenous microglia accumulated
on the Ab deposit may retain its activities, such as phagocytic
function and cytokine production.rats.4. Discussion
Previous reports demonstrated that microglia are able to
phagocytose Ab [4,13]. We also found that microglia markedly
phagocytosed Ab (see Supplemental information and Supple-
mental movie 1) and then degraded it by cathepsin D and/or
insulin-degrading enzyme-like proteases in the in vitro study
[14]. Neurons [15] and astrocytes [16] are also involved in Ab
clearance in in vivo brain. In the Ab42-injected rat, moderate
neuronal loss was induced and astrocytes were slightly acti-
vated in the region adjacent to the Ab deposit, whereas endog-
enous microglia were accumulated on the Ab deposit in our
present and previous studies [12]. In addition, we have found
regulatory factors of microglial Ab phagocytosis in in vitro
study, and the eﬀects of these factors were well reﬂected by
the Ab clearance in the Ab42-injected rat [11,12,14]. Thus,
Ab42-injected rats are a good model in the evaluation of
microglial contribution to Ab clearance in the in vivo brain.
Here, microglial transplantation did not seem to obviouslyinﬂuence residential cells around the Ab deposit, such as neu-
rons, astrocytes, and endogenous microglia in morphological
analysis by immunohistochemistry, while exogenous microglia
markedly inﬁltrated the Ab deposit. This inﬁltration may have
continued through the experimental period because the dark
area detected by MRI moved from the upper to middle and/
or lower regions of the Ab-injected hippocampus between 1
and 8 days. On the other hand, the dark area in the left lateral
ventricle was decreased at 8 days compared to that at 1 day.
Subsequently, lasting inﬁltration of exogenous microglia may
be responsible for the signiﬁcant increase of Ab clearance
and cytokine production after 7 days. Although we are not
sure about the mechanisms for the recruitment of exogenous
microglia in this study, we speculate that chemokines produced
by endogenous microglia and/or astrocytes activated around
the Ab deposit are involved in this recruitment.
In the AD brain, microglial phagocytosis is suggested to
work for Ab clearance as shown in a case report of the human
clinical trial of Ab immunotherapy [17]. This observation is
478 K. Takata et al. / FEBS Letters 581 (2007) 475–478supported by a report indicating positive correlations between
the accumulation of reactive microglia and the reduction of
senile plaques in an incomplete ischemic brain of a typical case
of AD [18]. Microglial Ab phagocytosis may have therapeutic
potential for AD; however, the non-speciﬁc activation of
microglia could alternatively cause harm as neuroinﬂamma-
tion [19]. Although further studies are required to conﬁrm
the microglial inﬂuence on neuronal viability, recent studies
suggest that the signaling of P2X7 receptors [20] and the
fractalkine receptor [21] may play a key role in microglial neu-
roprotection and the attenuation of microglial neurotoxicity,
respectively. Furthermore, several groups have recently dem-
onstrated that bone marrow-derived cells are able to diﬀeren-
tiate into functional microglia [22–24] and the implication of
bone marrow-derived microglia in Ab clearance is also sug-
gested [25]. Thus, bone marrow cells may be a suitable source
of microglial progenitors in clinical application. Additionally,
previous studies have reported that intra-arterially injected
microglia can migrate through an intact or injured blood–
brain barrier to the brain parenchyma [26,27].
Here, we demonstrated the possible usefulness of
exogenously transplanted microglia for the clearance of Ab
in the in vivo brain; however, further studies are needed before
the clinical use. In future studies, the methodology will be re-
quired to trace exogenous microglia after transplantation. In
this study, MRI is suggested to be one powerful tool as a
non-invasive means of detecting transplanted microglia. We
believe that investigations into microglia may provide a novel
insight for AD therapy.
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